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Abstract
It has been estimated that 30–40 percent of all cancers can be prevented by lifestyle and dietary
measures alone. Obesity, nutrient sparse foods such as concentrated sugars and refined flour
products that contribute to impaired glucose metabolism (which leads to diabetes), low fiber
intake, consumption of red meat, and imbalance of omega 3 and omega 6 fats all contribute to
excess cancer risk. Intake of flax seed, especially its lignan fraction, and abundant portions of fruits
and vegetables will lower cancer risk. Allium and cruciferous vegetables are especially beneficial,
with broccoli sprouts being the densest source of sulforophane. Protective elements in a cancer
prevention diet include selenium, folic acid, vitamin B-12, vitamin D, chlorophyll, and antioxidants
such as the carotenoids (α-carotene, β-carotene, lycopene, lutein, cryptoxanthin). Ascorbic acid
has limited benefits orally, but could be very beneficial intravenously. Supplementary use of oral
digestive enzymes and probiotics also has merit as anticancer dietary measures. When a diet is
compiled according to the guidelines here it is likely that there would be at least a 60–70 percent
decrease in breast, colorectal, and prostate cancers, and even a 40–50 percent decrease in lung
cancer, along with similar reductions in cancers at other sites. Such a diet would be conducive to
preventing cancer and would favor recovery from cancer as well.
Review
Background
The field of investigation of the role of nutrition in the
cancer process is very broad. It is becoming clearer as
research continues that nutrition plays a major role in
cancer. It has been estimated by the American Institute for
Cancer Research and the World Cancer Research Fund
that 30–40 percent of all cancers can be prevented by
appropriate diets, physical activity, and maintenance of
appropriate body weight [1]. It is likely to be higher than
this for some individual cancers.
Most of the research on nutrition and cancer has been
reductionist; that is, a particular food or a nutrient has
been studied in relation to its impact on tumor forma-
tion/regression or some other end point of cancer at a par-
ticular site in the body. These studies are very helpful in
seeing the details of the mechanisms of disease. However,
they do not help give an overall picture of how to prevent
cancer on a dietary level. Even less, they tell little of how
to eat when a person already has a cancer and would like
to eat a diet that is favorable to their recovery.
This review will focus on those dietary factors which has
been shown to be contribute to increased risk of cancer
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and then on those additional protective dietary factors
which reduce cancer risk. Finally, some whole-diet studies
will be mentioned which give a more complete picture of
how these individual factors work together to reduce can-
cer risk.
Over Consumption of Energy (Calories)
Eating too much food is one of the main risk factors for
cancer. This can be shown two ways: (1) by the additional
risks of malignancies caused by obesity, and (2) by the
protective effect of eating less food.
Obesity has reached epidemic proportions in the United
States. Sixty-four percent of the adult population is over-
weight or obese [2]. About 1 in 50 are now severely obese
(BMI > 40 kg/m2) [3]. Mokdad et al [4] found that poor
diet and physical inactivity was the second leading cause
of death (400,000 per year in the USA), and would likely
overtake tobacco as the leading cause of death.
It was estimated in a recent study, from a prospective can-
cer prevention cohort, that overweight and obesity
accounted for 14 percent of all cancer deaths in men and
20 percent of those in women [5]. Significant positive
associations were found between obesity and higher
death rates for the following cancers: esophagus, colon
and rectum, liver, gallbladder, pancreas, kidney, stomach
(in men), prostate, breast, uterus, cervix, and ovary [5].
The authors estimated that over 90,000 cancer deaths per
year could be avoided if the adult population all main-
tained a normal weight (BMI < 25.0) [5]. Clearly, obesity
is a major risk factor for cancer.
On the other side, careful menu planning brings about an
approach entitled CRON-Calorie Restriction with Opti-
mal Nutrition. The basic idea is to eat a reduced amount
of food (about 70–80 percent of the amount required to
maintain "normal" body weight) while still consuming all
of the necessary amounts of vitamins, minerals, and other
necessary nutrients. The only restriction is the total
amount of energy (calories) that is consumed. While
being difficult to practice, this approach has a lot of scien-
tific merit for being able to extend average life spans of
many species of animals including rats, mice, fish, and
possibly primates (currently being tested). Along with this
life span extension is a reduction in chronic diseases that
are common to mankind, reviewed in Hursting et al [6]. A
recent meta-analysis of 14 experimental studies found
that energy restriction resulted in a 55% reduction in
spontaneous tumors in laboratory mice [7]. Calorie
restriction inhibited induced mammary tumors in mice
[8] and suppressed implanted tumor growth and pro-
longed survival in energy restricted mice [9]. Among
Swedish women who had been hospitalized for anorexia
nervosa (definitely lower caloric intake, but not adequate
nutrition) prior to age 40, there was a 23% lower inci-
dence of breast cancer for nulliparous women and a 76%
lower incidence for parous women [10]. So, too many cal-
ories is definitely counter-productive, and slightly less
than normal is very advantageous.
Glucose Metabolism
Refined sugar is a high energy, low nutrient food – junk
food. "Unrefined" sugar (honey, evaporated cane juice,
etc) is also very concentrated and is likely to contribute to
the same problems as refined sugar. Refined wheat flour
products are lacking the wheat germ and bran, so they
have 78 percent less fiber, an average of 74 percent less of
the B vitamins and vitamin E, and 69 percent less of the
minerals (USDA Food database, data not shown). Con-
centrated sugars and refined flour products make up a
large portion of the carbohydrate intake in the average
American diet. One way to measure the impact of these
foods on the body is through the glycemic index.
The glycemic index is an indication of the blood sugar
response of the body to a standardized amount of carbo-
hydrate in a food. The glycemic load takes into account
the amount of food eaten. An international table of the
glycemic index and glycemic load of a wide variety of
foods has been published [11].
Case-control studies and prospective population studies
have tested the hypothesis that there is an association
between a diet with a high glycemic load and cancer. The
case control studies have found consistent increased risk
of a high glycemic load with gastric [12], upper aero diges-
tive tract [13], endometrial [14], ovarian [15], colon or
colorectal cancers [16,17]. The prospective studies' results
have been mixed. Some studies showed increased risk of
cancer in the whole cohort with high glycemic load [18-
20]; some studies found only increased risk among sub-
groups such as sedentary, overweight subjects [21-24];
other studies concluded that there was no increased risk
for any of their cohort [25-28]. Even though there were no
associations between glycemic load and colorectal, breast,
or pancreatic cancer in the Nurses' Health Study there was
still a strong link between diabetes and colorectal cancer
[29].
Perhaps the dietary glycemic load is not consistently
related to glucose disposal and insulin metabolism due to
individual's different responses to the same glycemic load.
Glycated hemoglobin (HbA1c) is a time-integrated meas-
urement of glucose control, and indirectly, of insulin lev-
els. Increased risk in colorectal cancer was seen in the
EPIC-Norfolk study with increasing HbA1c; subjects with
known diabetes had a three-fold increased risk of colorec-
tal cancer [30]. In a study of a cohort in Washington
county, Maryland, increased risk of colorectal cancer wasNutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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seen in subjects with elevated HbA1c, BMI > 30 kg/m2, or
who used medications to control diabetes [31]. However,
glycated hemoglobin was not found to be associated with
increased risk of colorectal cancer in a small nested case-
control study within the Nurses' Health Study [32]. Ele-
vated fasting glucose, fasting insulin, 2 hour levels of glu-
cose and insulin after an oral glucose challenge, and larger
waist circumference were associated with a higher risk of
colorectal cancer [33]. In multiple studies diabetes has
been linked with increased risk of colorectal cancer [34-
37], endometrial cancer [38], and pancreatic cancer
[35,39]. It is clear that severe dysregulation of glucose
metabolism is a risk factor for cancer. Foods which con-
tribute to hyperinsulinemia, such as refined sugar, foods
containing refined sugar, and refined flour products
should be avoided and eliminated from a cancer protec-
tive diet.
Low Fiber
Unrefined plant foods typically have an abundance of
fiber. Dairy products, eggs, and meat all have this in com-
mon – they contain no fiber. Refined grain products also
have most of the dietary fiber removed from them. So, a
diet high in animal products and refined grains (a typical
diet in the USA) is low in fiber. In prospective health stud-
ies low fiber was not found to be a risk for breast cancer
[25]. It is possible that fiber measurements are just a sur-
rogate measure for unrefined plant food intake. Slattery et
al [40] found an inverse correlation between vegetable,
fruit and whole grain intake plant food intake and rectal
cancer, while refined grains were associated with
increased risk of rectal cancer. A threshold of about 5 daily
servings of vegetables was needed to reduce cancer risk
and the effect was stronger among older subjects [40].
Many other nutrients are co-variants with fiber, including
folic acid, which is covered in detail below.
Red Meat
Red meat has been implicated in colon and rectal cancer.
A Medline search in February 2003 uncovered 26 reports
of human studies investigating the link between diet and
colon or colorectal cancer. Of the 26 reports, 21 of them
reported a significant positive relationship between red
meat and colon or colorectal cancer [17,41-64]. A recent
meta-analysis also found red meat, and processed meat, to
be significantly associated with colorectal cancer [65].
Meat, and the heterocyclic amines formed in cooking,
have been correlated to breast cancer in a case-control
study in Uruguay as well [66].
Omega 3:6 Ratio Imbalance
Omega 3 fats (alpha-linolenic acid, EPA, DHA) have been
shown in animal studies to be protect from cancer, while
omega 6 fats (linoleic acid, arachidonic acid) have been
found to be cancer promoting fats. Now there have been
several studies that have tested this hypothesis in relation
to breast cancer, summarized in Table 1. Except for the
study by London et al [67], all of these studies found an
association between a higher ratio of N-3 to N-6 fats and
reduced risk of breast cancer. Long chain N-3 and N-6 fats
have a different effect on the breast tumor suppressor
genes BRCA1 and BRCA2. Treatment of breast cell cultures
with N-3 fats (EPA or DHA) results in increased expres-
sion of these genes while arachadonic acid had no effect
[68]. Flax seed oil and DHA (from an algae source) both
can be used to increase the intake of N-3 fat, with DHA
being a more efficient, sure source.
Flax seed
Flax seed provides all of the nutrients from this small
brown or golden hard-coated seed. It is an excellent source
of dietary fiber, omega 3 fat (as alpha-linolenic acid), and
lignans. The lignans in flax seed are metabolized in the
digestive tract to enterodiol and enterolactone, which
have estrogenic activity. In fact, flax seed is a more potent
source of phytoestrogens than soy products, as flax seed
intake caused a bigger change in the excretion of 2-
hydroxyestrone compared to soy protein [69].
Ground flax seeds have been studied for its effect on can-
cer, including several excellent studies by Lilian Thomp-
son's research group at the University of Toronto. In one
study the flax seed, its lignan fraction, or the oil were
added to the diet of mice who had previously been
administered a chemical carcinogen to induce cancer. All
three treatments reduced the established tumor load; the
lignan fraction containing secoisolariciresinol diglycoside
(SDG) and the flax seed also reduced metastasis [70]. In
another study the flax lignan SDG was fed to mice starting
1 week after treatment with the carcinogen dimethylben-
zanthracene. The number of tumors per rat was reduced
by 46% compared to the control in this study [71]. Flax or
its lignan (SDG) were tested to see if they would prevent
melanoma metastasis. The flax or lignan fraction were fed
to mice two weeks before and after injection of melanoma
cells. The flax treatment (at 2.5, 5, or 10% of diet intake)
resulted in a 32, 54, and 63 percent reduction in the
number of tumors, compared to the control [72]. The
SDG, fed at amounts equivalent to the amount in 2.5, 5,
or 10% flax seed, also reduced the tumor number, from a
median number of 62 in the control group to 38, 36, and
29 tumors per mouse in the SDG groups, respectively
[73].
More recently Thompson's research group studied mice
that were injected with human breast cancer cells. After
the injection the mice were fed a basal diet (lab mouse
chow) for 8 weeks while the tumors grew. Then one group
continued the basal diet and another was fed a 10% flaxNutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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seed diet. The flax seed reduced the tumor growth rate and
reduced metastasis by 45% [74].
Flax seed has been shown to enhance mammary gland
morphogenesis or differentiation in mice. Nursing dams
were fed the 10% flax seed diet (or an equivalent amount
of SDG). After weaning the offspring mice were fed a reg-
ular mouse chow diet. Researchers then examined the
female offspring and found an increased number of termi-
nal end buds and terminal ducts in their mammary glands
with more epithelial cell proliferation, all demonstrating
that mammary gland differentiation was enhanced [75].
When these female offspring were challenged with a car-
cinogen to induce mammary gland tumors there were sig-
nificantly lower incidence of tumors (31% and 42% lower
in the flax seed and SDG groups, respectively), signifi-
cantly lower tumor load (51% and 62% lower in the flax
seed and SDG groups, respectively), significantly lower
mean tumor size (44% and 68% lower in the flax seed and
SDG groups, respectively), and significantly lower tumor
number (47% and 45% lower in the flax seed and SDG
groups, respectively) [76]. So, flax seed and its lignan were
able to reduce tumor growth (both in number and size of
tumors), prevent metastasis, and even cause increased dif-
ferentiation of mouse mammary tissue in suckling mice,
making the offspring less susceptible to carcinogenesis
even when not consuming any flax products.
Other researchers have tested flax seed and prostate can-
cer. In an animal model using mice, Lin et al [77] found
that a diet supplemented with 5% flax inhibited the
growth and development of prostate cancer in their exper-
imental mouse model. A pilot study of 25 men who were
scheduled for prostatectomy surgery were instructed to eat
a low-fat diet (20% or less of energy intake) and to supple-
ment with 30 g of ground flaxseed per day. During the fol-
low-up of an average of 34 days there were significant
changes in serum cholesterol, total testosterone, and the
free androgen index [78]. The mean proliferation index of
the experimental group was significantly lower and apop-
Table 1: Breast Cancer and Omega 3:6 Ratio.
Reference # of cases w/ 
breast 
cancer
# of controls Post / pre 
Menopausal
Measure of n-3 / 
n-6 fat
Outcome Odds ratio (95% 
Confidence Interval)
[183] 565 554 (population 
and hospital)
Pre & post Diet FFQ ↑N3/N6 ratio in 
premenopausal women = 
Non-signif. ↓Breast cancer 
risk
0.59 (0.29–1.19)
In study site with population 
controls, find ↑N3/N6 ratio 
= Signif ↓Breast Cancer risk
0.50 (0.27, 0.95)
[184] EURAMIC 
study
Nested case-
control study in 
population study
Post Adipose tissue 4 out of 5 centers showed 
↑N3/N6 ratio = ↓Breast 
Cancer risk
0.65 (p for trend = 
0.55)
[185] 241 88 w/ benign 
breast disease
Both Adipose tissue ↑DHA = ↓Breast cancer 0.31 (0.13–0.75)
↑Ratio of long chain N-3:N-6 
fat = ↓Breast cancer
0.33 (0.17–0.66)
[186] 73 74 w/ macromastia ? Adipose tissue N-6 fat content signif. higher 
in cases
P = 0.02
For given level of N-6 fat, 
EPA and DHA had a 
protective effect
P = 0.06
[187] 71 (within 
ORDET study)
142 (nested case 
control)
Post RBC membranes ↑DHA = ↓Breast cancer 0.44 (0.21–0.92)
[67] 380 397 Post Adipose tissue No associations between N-
3:N-6 ratio and breast 
cancer
[188] 314 (within 
Singapore 
Chinese Health 
study)
Diet, FFQ ↑Intake of N-3 fat from fish / 
shellfish = ↓Breast cancer, 
for all 3 highest quartiles
0.74 (0.58–0.94)
Among women in lowest 
quartile of N-3 fat intake, 
↑N-6 fat intake = ↓Breast 
cancer
1.87 (1.06–3.27)Nutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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totic indexes higher compared to historical matched con-
trols. Ground flax seed may be a very beneficial food for
men battling prostate cancer. However, a meta-analysis of
nine cohort and case-control studies revealed an associa-
tion between flax seed oil intake or high blood levels of
alpha-linolenic acid and prostate cancer risk [79]. It is
quite likely that the lignans in flax seed are a major com-
ponent of flax's anti-cancer effects so that flax oil without
the lignans is not very beneficial. Some brands of flax seed
oil retain some of the seed particulate because of the ben-
eficial properties of the lignans.
Fruits and Vegetables
One of the most important messages of modern nutrition
research is that a diet rich in fruits and vegetables protects
against cancer. (The greatest message is that this same diet
protects against almost all other diseases, too, including
cardiovascular disease and diabetes.) There are many
mechanisms by which fruits and vegetables are protective,
and an enormous body of research supports the recom-
mendation for people to eat more fruits and vegetables.
Block et al [80] reviewed about 200 studies of cancer and
fruit and vegetable intake. A statistically significant protec-
tive effect of fruits and vegetables was found in 128 of 156
studies that gave relative risks. For most cancers, people in
the lower quartile (1/4 of the population) who ate the
least amount of fruits and vegetables had about twice the
risk of cancer compared to those who in the upper quartile
who ate the most fruits and vegetables. Even in lung can-
cer, after accounting for smoking, increasing fruits and
vegetables reduces lung cancer; an additional 20 to 33 per-
cent reduction in lung cancers is estimated [1].
Steinmetz and Potter reviewed the relationship between
fruits, vegetables, and cancer in 206 human epidemio-
logic studies and 22 animal studies [81]. They found "the
evidence for a protective effect of greater vegetable and
fruit consumption is consistent for cancers of the stom-
ach, esophagus, lung, oral cavity and pharynx,
endometrium, pancreas, and colon." Vegetables, and par-
ticularly raw vegetables, were found to be protective; 85%
of the studies that queried raw vegetable consumption
found a protective effect. Allium vegetables, carrots, green
vegetables, cruciferous vegetables, and tomatoes also had
a fairly consistent protective effect [81]. Allium vegetables
(garlic, onion, leeks, and scallions) are particularly potent
and have separately been found to be protective for stom-
ach and colorectal cancers [82,83] and prostate cancer
[84].
There are many substances that are protective in fruits and
vegetables, so that the entire effect is not very likely to be
due to any single nutrient or phytochemical. Steinmetz
and Potter list possible protective elements: dithiolth-
iones, isothiocyanates, indole-32-carbinol, allium com-
pounds, isoflavones, protease inhibitors, saponins,
phytosterols, inositol hexaphosphate, vitamin C, D-
limonene, lutein, folic acid, beta carotene (and other car-
otenoids), lycopene, selenium, vitamin E, flavonoids, and
dietary fiber [81].
A joint report by the World Cancer Research Fund and the
American Institute for Cancer Research found convincing
evidence that a high fruit and vegetable diet would reduce
cancers of the mouth and pharynx, esophagus, lung,
stomach, and colon and rectum; evidence of probable risk
reduction was found for cancers of the larynx, pancreas,
breast, and bladder [1].
Many of the recent reports from prospective population-
based studies of diet and cancer have not found the same
protective effects of fruits and vegetables that were
reported earlier in the epidemiological and case-control
studies [reviewed in [85]]. One explanation is that peo-
ple's memory of what they ate in a case-cohort study may
have been tainted by their disease state. Another problem
might be that the food frequency questionnaires (FFQ)
used to measure food intake might not be accurate
enough to detect differences. Such a problem was noted in
the EPIC study at the Norfolk, UK site. Using a food diary
the researchers found a significant correlation between
saturated fat intake and breast cancer, but using a FFQ
there was no significant correlation [86]. So, inaccurate
measurement of fruit and vegetable intake might be part
of the explanation as well.
It must be noted that upper intakes of fruits and vegeta-
bles in these studies are usually within the range of what
people on an American omnivorous diet normally eat. In
the Nurses Health Study the upper quintiles of fruit and
vegetable intake were 4.5 and 6.2 servings/day,
respectively [87]. Similarly, the upper quintiles of fruit
and vegetable intake in the Health Professionals Follow-
up Study were 4.3 and 5.4 serving/day for fruits and vege-
tables, respectively [87]. Intakes of fruits and vegetables
on the Hallelujah Diet are much higher, with median
reported intakes of six servings of fruits (646 g/day) and
eleven servings of vegetables per day (971 g/day) [88] in
addition to a green powder from the juice of barley leaves
and alfalfa that is equivalent to approximately another
100 g/day of fresh dark greens. So, it is very possible that
the range of intakes in the prospective population based
studies do not have a wide enough intake on the upper
end to detect the true possible impact of a very high intake
of fruits and vegetables on cancer risk.
Cruciferous Vegetables
Cruciferous vegetables (broccoli, cauliflower, cabbage,
Brussels sprouts) contain sulforophane, which has anti-Nutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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cancer properties. A case-control study in China found
that intake of cruciferous vegetables, measured by urinary
secretion of isothiocyanates, was inversely related to the
risk of breast cancer; the quartile with the highest intake
only had 50% of the risk of the lowest intake group [89].
In the Nurses' Health Study a high intake of cruciferous
vegetables (5 or more servings/week vs less than two serv-
ings/week) was associated with a 33% lower risk of non-
Hodgkin's lymphoma [90]. In the Health Professionals
Follow-up Study bladder cancer was only weakly associ-
ated with low intake of fruits and vegetables, but high
intake (5 or more servings/week vs 1 or less servings/wk)
of cruciferous vegetables was associated with a statistically
significant 51% decrease in bladder cancer [91]. Also,
prostate cancer risk was found to be reduced by crucifer-
ous vegetable consumption in a population-based case-
control study carried out in western Washington state.
Three or more servings per week, compared to less than
one serving of cruciferous vegetables per week resulted in
a statistically significant 41% decrease in prostate cancer
risk [92]. Similar protective effects of cruciferous vegeta-
bles were seen in a multi-ethnic case-control study [93]. A
prospective study in Shanghai, China found that men
with detectable amounts of isothiocyanates in their urine
(metabolic products that come from cruciferous vegeta-
bles) had a 35% decreased risk of lung cancer. Among
men that had one or two genetic polymorphisms that
caused them to eliminate these isothiocyanates slower
there was a 64% or 72% decreased risk of lung cancer,
respectively [94].
Broccoli sprouts have a very high concentration of sul-
forophane since this compound originates in the seed and
is not made in the plant as it grows [95,96]. One sprout
contains all of the sulforophane that is present in a full-
grown broccoli plant. So, if sulforophane is especially can-
cer-protective, it would seem reasonable to include some
broccoli sprouts in an anti-cancer diet.
Selenium
Selenium is a mineral with anti-cancer properties. Many
studies in the last several years have shown that selenium
is a potent protective nutrient for some forms of cancer.
The Arizona Cancer Center posted a selenium fact sheet
listing the major functions of selenium in the body [97].
These functions are as follows:
1. Selenium is present in the active site of many enzymes,
including thioredoxin reductase, which catalyze oxida-
tion-reduction reactions. These reactions may encourage
cancerous cells to under apoptosis.
2. Selenium is a component of the antioxidant enzyme
glutathione peroxidase.
3. Selenium improved the immune systems' ability to
respond to infections.
4. Selenium causes the formation of natural killer cells.
5. P450 enzymes in the liver may be induced by selenium,
leading to detoxification of some carcinogenic molecules.
6. Selenium inhibits prostaglandins that cause
inflammation.
7. Selenium enhances male fertility by increased sperm
motility.
8. Selenium can decrease the rate of tumor growth.
Table 2: Prospective Nested Case Control Studies of Selenium and Prostate Cancer.
Reference Study # Cases # Controls Outcomes Comment
[189] Physicians Health 
Study
586 577 ↑Se = ↓risk of advance prostate cancer (OR 
= 0.52, 95% CI = 0.28–0.98)
Result only in men with PSA ≥ 4 ng/
mL
[190] Netherlands Cohort 
Study
540 1,211 ↑Se = ↓risk prostate cancer (OR for quintiles 
of Se = 1.0, 1.05, 0.69, 0.75, 0.69; 95% CI = 
0.48–0.99)
Results greatest in ex-smokers
[191] Baltimore Longitudinal 
Study of Aging
52 96 ↑Se = ↓risk prostate cancer (OR for quartiles 
of Se = 1.0, 0.15, 0.21, 0.24
[192] Washington County, 
Maryland
117 233 Top 4/5 of Se had reduction in prostate 
cancer risk; statistically significant result for 
Se only when γtocopherol levels were high
Men in top quintile of serum 
γtocopherol had 5-fold reduced risk 
of prostate cancer compared to 
lowest quintile
[193] Health Professional 
Follow-up Study
181 181 ↑Se = ↓risk of advanced prostate cancer Adjusted OR = 0.35 (95% CI = 
0.16–0.78)
[194] Prospective study ↑Se = ↓risk of gastrointestinal and prostate 
cancer
Results not statistically significantNutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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A serendipitous randomized, double-blind, controlled
trial of a 200 µg/day selenium supplement in the south-
eastern region of the USA (where soil selenium levels are
low) found that the primary endpoints of skin cancer were
not improved by the selenium supplement, but that other
cancer incidence rates were decreased by selenium
[98,99]. There was a significant reduction in total cancer
incidence (105 vs 137 cases, P = 0.03), prostate cancer (22
vs 42 cases, P = 0.005), a marginally significant reduction
in colorectal cancer incidence (9 vs 19 cases, P = 0.057),
and a reduction in cancer mortality, all cancer sites (40 vs
66 deaths, P = 0.008) (selenium versus control group
cases reported, respectively) [98]. The selenium supple-
ment was most effective in ex-smokers and for those who
began the study with the lowest levels of serum selenium.
Several prospective studies have also examined the role of
selenium in cancer prevention, particularly for prostate
cancer, summarized in Table 2.
Overall, it appears that poor selenium levels, especially for
men, are a cancer risk. If a person has low selenium levels
and other antioxidant defenses are also low the cancer risk
is increased even further. Women do not appear to be as
sensitive to selenium, as breast cancer has not been found
to be influenced by selenium status in several studies
[100-104], although both men and women were found to
be protected by higher levels of selenium from colon can-
cer [100] and lung cancer [105,106]. Good vegetarian
sources of selenium are whole grains and legumes grown
in selenium-rich soil in the western United States, brazil
nuts (by far the most dense source of selenium), nutri-
tional yeast, brewers yeast, and sunflower seeds.
Chlorophyll
All green plants also contain chlorophyll, the light-collect-
ing molecule. Chlorophyll and its derivatives are very
effective at binding polycyclic aromatic hydrocarbons
(carcinogens largely from incomplete combustion of
fuels), heterocyclic amines (generated when grilling
foods), aflatoxin (a toxin from molds in foods which
causes liver cancer), and other hydrophobic molecules.
The chlorophyll-carcinogen complex is much harder for
the body to absorb, so most of it is swept out with the
feces. The chemoprotective effect of chlorophyll and its
derivatives has been tested in laboratory cell cultures and
animals [107,108]. There is so much compelling evidence
for anti-carcinogenic effects of chlorophyll that a prospec-
tive randomized controlled trial is being conducted in
Qidong, China to see if chlorophyllin can reduce the
amount of liver cancer cases, which arise from aflatoxin
exposure in their foods (corn, peanuts, soy sauce, and fer-
mented soy beans). A 55% reduction in aflatoxin-DNA
adducts were found in the group that took 100 mg of
chlorophyllin three times a day [109]. It was supposed
that the chlorophyllin bound up aflatoxins, but there were
chlorophyllin derivatives also detected in the sera (which
had a green tint to it) of the volunteers who took the sup-
plement, indicating a possible role in the body besides
binding carcinogens in the gut [110].
Protective Vitamins
Vitamin B-12
Vitamin B-12 has not been proven to be an anti-cancer
agent, but there is some evidence indicating that it could
be beneficial. The form of administered vitamin B-12 may
be important.
Some experimental cancer studies have been carried out
with various forms of vitamin B-12. Methylcobalamin
inhibited tumor growth of SC-3 injected into mice [111],
and caused SC-3 mouse mammary tumor cells to undergo
apoptosis, even when stimulated to grow by the presence
of growth-inducing androgen [112]. Methylcobalamin,
but not cyanocobalamin, increased the survival time of
mice bearing implanted leukemia tumor cells [113]. 5'-
deoxyadenosylcobalamin and methylcobalamin, but not
cyanocobalamin, were shown to be effective cytotoxic
agents [114]. Methylcobalamin also was able to increase
survival time and reduce tumor growth in laboratory mice
[115].
Laboratory mechanistic evidence for the effects of vitamin
B12 were seen in a laboratory study with vitamin B-12
deficient rats. Choi et al [116] found that the colonic DNA
of the B-12 deficient rats had a 35% decrease in genomic
methylation and a 105% increase in uracil incorporation,
both changes that could increase risk of carcinogenesis. In
two prospective studies (one in Washington Country,
Maryland and the Nurses' Health Study) a relation
between lower vitamin B12 status (but not deficiency)
and statistically significant higher risk of breast cancer was
found [117,118]. So, there is evidence from laboratory
studies, prospective cohort studies, and mechanistic stud-
ies showing that vitamin B-12 is an important nutrient for
genetic stability, DNA repair, carcinogenesis, and cancer
therapy.
Folic Acid
Folic acid is the dark green leafy vegetable vitamin. It has
an integral role in DNA methylation and DNA synthesis.
Folic acid works in conjunction with vitamin B-6 and vita-
min B-12 in the single carbon methyl cycle. If insufficient
folic acid is not available uracil is substituted for thymi-
dine in DNA, which leads to DNA strand breakage. About
10% of the US population (and higher percentages
among the poor) has low enough intakes of folic acid to
make this a common problem [119]. As shown in Tables
3 and 4, many studies have found a significant reduction
in colon, rectal, and breast cancer with higher intakes of
folic acid and their related nutrients (vitamin B-6 and B-Nutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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Table 3: Folate and Colon / Rectal Cancer.
Reference Study # Cases # Controls Outcomes Comment
[195] Case / control USA 35 64 Folate supplementation = 62% 
lower incidence of neoplasia
result not SS
[196] Case / control NY 
state
800 Matched neighbor-
hood controls
↑Folate = ↓rectal cancer, OR = 
0.5 men, OR = 0.31, women 
Folate no effect for colon cancer
SS
[197] Case / control 
Majorca, Spain
286 498 Colon cancer related to total 
calories, cholesterol, animal 
protein, low fiber, low folic acid
.
[198] Case / Control Wash. 
state
424 414 ↑Alcohol = ↑cancer risk; ↑fiber = 
↓risk; no relation to folate intake
2.5X risk for 30 g/day 
alcohol
[199] Nurses' Health Study 
& Health Professionals 
Follow-up Study
564 women, 331 men ↑folate = ↓risk of colorectal 
adenoma: ORwomen = 0.66, ORmen 
= 0.63
[200] Case / Control, Italy 1,326 2,024 hospital 
controls
Protective trends for β-carotene, 
ascorbic acid, vit E, and folate (OR 
= 0.32, 0.40, 0.60, 0.52, 
respectively)
Similar for colon and 
rectal cancer
[201] US male health 
professional cohort
205 ↑Alcohol = ↑colon cancer (OR = 
2.07 for ≥ 2 drinks/day; folate 
weakly protective; ↑Alcohol + 
↓folate = ↑colon cancer risk (OR 
= 3.30)
[202] α-tocopherol, β-
carotene study cohort 
of smokers
144 276 ↑dietary folate = ↓colon cancer 
(OR = 1.0, 0.40, 0.34, 0.51, P-
trend = 0.15);
alcohol intake 
increased risk
[203] Case control, 
population based
Composite dietary profile (alcohol 
intake, methionine, folate, vit B12, 
B6) trend of increasing risk for 
high risk group
Marginal SS
[204] Nurses' Health Study 442 ↑folate intake = ↓colon cancer 
(OR = 0.69); long-term use of 
multi-vitamins beneficial
Folate intake includes 
multi-vitamins
[205] NYU Women's 
Health Study
105 523 ↑folate = ↓colorectal cancer risk 
(OR = 0.52, P-trend = 0.04
Alcohol increased risk
[206] NHANES I 
Epidemiologic Follow-
up Study
↑folate = ↓colon cancer (ORmen = 
0.40, P-trend = 0.03; ↑alcohol, 
↓folate = ↑colon cancer (ORmen = 
2.67
Results not stat. signif 
in women
[207] Nurses' Health Study 535 ↑folate intake = ↓colon cancer in 
women with family history (OR = 
0.48)
Folate effect greater in 
women with family 
history
[208] Canadian National 
Breast Screening 
Study
295 5,334 ↑folate = ↓colorectal cancer (OR 
= 0.6, P-trend = 0.25
Results not SS
[209] Prospective cohort in 
The Netherlands
1,171 Rectal: OR, men 0.66, women no 
trend
Trends SS only in men
[210] Case / Control Italy 1,953 4,154 ↑folate = ↓colorectal cancer (OR 
= 0.72)
Population drinks 
alcohol regularly
[211] Iowa Women's health 
Study
721 ↑folate + (↑B12 or ↑B6) = ↓colon 
cancer (OR = 0.59, 0.65, 
respectively
Nutrients not 
independent, alcohol 
increases risk
[212] Case / Control NC 
state
613 996 ↑β-carotene, vit C, calcium = 40–
60 % ↓risk colon cancer in whites; 
in African Americans ↑ vit C and E 
= 50–70% ↓risk colon cancer; no 
relation to folate to cancer risk
Colon cancer rates 
higher in Aftrican 
Americans in NC; due 
to less UV light 
absorption with dark 
skin?
[213] Wheat Bran Fiber 
trial, test for 
recurrence of 
adenoma polyps
1,014 men and 
women
↑homocysteine = ↑risk (OR = 
0.69); ↑plasma folate = ↓risk (OR 
= 0.66) ↑folate or B6 intake (diet + 
supplements) = ↓risk (OR = 0.61
SS; cut-off for highest 
quartile is 664 µg/day 
(way above RDA)
SS = statistically significantNutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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12). Alcohol is an antagonist of folate, so that drinking
alcoholic beverages greatly magnifies the cancer risk of a
low-folate diet. Genetic polymorphisms (common single
DNA base mutations resulting in a different amino acid
encoded into a protein) in the methylenetetrahydrofolate
reductase and the methionine synthase genes which
increase the relative amount of folate available for DNA
synthesis and repair also reduces the risk of colon cancer
[120-123]. Cravo et al [124] used 5 mg of folic acid a day
(a supraphysiological dose) in a prospective, controlled,
cross-over study of 20 patients with colonic adenoma pol-
yps. They found that the folic acid could reverse DNA
hypomethylation in 7 of 12 patients who had only one
polyp.
Folate may be more important for rapidly dividing tissue,
like the colonic mucosa. Therefore, the cancer risk associ-
ated with low folate intake is probably higher for colon
cancer than for breast cancer. Most of the breast cancer
studies only found a protective effect of folate among
women who consumed alcohol (see Table 4). However,
among women residents of Shanghai who consumed no
alcohol, no vitamin supplements and ate unprocessed,
unfortified foods there was a 29% decreased risk of breast
cancer among those with the highest intake of folate
[125]. So, there may be a true protective effect that is
masked in the western populations by so many other risk
factors. Two studies showed that the risk of cancer due to
family history can be modified by high folate intake, so a
prudent anti-cancer diet would be high in dark green leafy
vegetables. The mean intake of folic acid on the Hallelu-
jah Diet was 594 µg/day for men and 487 µg/day for
women [88].
Vitamin D
Vitamin D is produced primarily from the exposure of the
skin to sunshine. Even casual exposure of the face, hands,
and arms in the summer generates a large amount of vita-
min D. In fact, simulated sunshine, equivalent to standing
on a sunny beach until a slight pinkness of the skin was
detected, was equivalent to a 20,000 IU oral dose of vita-
min D2 [126]. (Note that the RDA is 400 IU for most
adults.) It has been estimated that 1,000 IU per day is the
minimal amount needed to maintain adequate levels of
vitamin D in the absence of sunshine [126], and that up
to 4,000 IU per day can be safely used with additional
benefit [127].
The concentration of the active hormonal form of vitamin
D is tightly regulated in the blood by the kidneys. This
active hormonal form of vitamin D has the potent anti-
cancer properties. It has been discovered that various
types of normal and cancerous tissues, including prostate
cells [128], colon tissue [129], breast, ovarian and cervical
Table 4: Prospective Studies of Folate and Breast Cancer.
Reference Study # Cases # Controls Outcomes Comment
[214] Nurses' Health Study 3,483 ↓folate intake + alcohol = ↑risk of breast 
cancer (OR = 0.55, P-trend = 0.001)
Folate intake not associated 
with overall risk of breast 
cancer
[215] Canadian National Breast 
Screening Study
1,336 5,382 ↓folate intake + alcohol = ↑risk of breast 
cancer (OR = 0.34, P-trend = 0.004)
Folate intake not associated 
with overall risk of breast 
cancer
[216] Prospective study in USA 
with postmenopausal 
women
1,586 Among drinkers, ↓folate intake = ↑breast 
cancer risk (OR = 1.59)
No association in overall 
cohort
[125] Shanghai Breast Cancer 
Study, China
1,321 1,382 ↑folate intake = ↓ risk (OR = 0.71, P-
trend = 0.05); ↑folate, ↑methionine, ↑B6, 
↑B12 = ↓risk (OR = 0.47, P-trend = 0.01)
No alcohol, no supplements, 
unprocessed, unfortified foods
[217] Nurses' Health Study II, 
study of premenopausal 
women
714 Vitamin A protective (OR = 0.28); 
Vitamins C, E, and folate not associated 
with risk.
[118] Nurses' Health Study 712 712 matched ↑plasma folate = ↓risk (OR = 0.73, P-
trend = 0.06). For women who drank 
alcohol, ↑plasma folate even more 
protective, OR = 0.11.
↑plasma B6 and plasma B12 
were also protective
[218] Prospective study in USA 
with postmenopausal 
women
1,823, 308 
with family 
history (FH)
FH- +Alcohol = ↑risk (OR = 1.40) FH- + 
Alcohol + ↑folate = normal risk; FH+ 
↓folate = ↑risk for drinkers (OR = 2.21) 
and non-drinkers (OR = 2.39); FH+ 
+Alcohol + ↑folate = ↑risk (OR = 1.67); 
FH+ + ↑folate = normal risk
Women with family history of 
breast cancer can reduce risk 
by increasing folate intake and 
not drinking.
FH = Family HistoryNutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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tissue [130], pancreatic tissue [131] and a lung cancer cell
line [132] all have the ability to convert the major circu-
lating form of vitamin D, 25(OH)D, into the active hor-
monal form, 1,25(OH)2D. So, there is a local mechanism
in many tissues of the body for converting the form of
vitamin D in the body that is elevated by sunshine expo-
sure into a hormone that has anticancer activity.
Indeed, 25(OH)D has been shown to inhibit growth of
colonic epithelial cells [133], primary prostatic epithelial
cells [134], and pancreatic cells [131]. So, the laboratory
work is confirming what had been seen some time ago in
ecological studies of populations and sunshine exposure.
The mortality rates for colon, breast, and ovary cancer in
the USA show a marked north-south gradient [135]. In
ecological studies of populations and sunlight exposure
(no individual data) sunlight has been found to have a
protective effect for prostate cancer [136], ovarian cancer
[137], and breast cancer [138]. Recently Grant found that
sunlight was also protective for bladder, endometrial,
renal cancer, multiple myeloma, and Non-Hodgkins lym-
phoma in Europe [139] and bladder, esophageal, kidney,
lung, pancreatic, rectal, stomach, and corpus uteri cancer
in the USA [140]. Several prospective studies of vitamin D
and cancer have also shown a protective effect of vitamin
D (see Table 5). It could be that sunshine and vitamin D
are protective factors for cancers of many organs that can
convert 25(OH)D into 1,25(OH)D2.
Antioxidants
α- and β-Carotene and other Carotenoids
Carotenoids have been studied vigorously to see if these
colorful compounds can decrease cancer risk. In ecologi-
cal studies and early case-control studies it appeared that
β-carotene was a cancer-protective agent. Randomized
controlled trials of β-carotene found that the isolated
nutrient was either neutral [141] or actually increased risk
of lung cancer in smokers [142,143]. Beta-carotene may
be a marker for intake of fruits and vegetables, but it does
not have a powerful protective effect in isolated pharma-
cological doses.
Table 5: Prospective Studies of Vitamin D and Cancer.
Reference Study Vit D measure # Cases # Controls Outcomes Comment
[219] 19-year cohort study 
of 1,954 men
Diet history ↑vit D + calcium = ↓colorectal 
cancer (rates for lowest to 
highest intakes were 38.9, 24,5, 
22,5 and 14.3/1000 population
Significant effect even 
after adjustments for 
confounding factors; 2.7 
fold reduction.
[220] Washington county, 
Maryland cohort
Serum 25(OH)D 34 67 matched ↑serum vit D = ↓colon cancer. 
Relative risk was 0.25 for 3rd 
quintile and 0.20 for 4th quintile.
4–5 fold reduction
[221] Physicians' Health 
Study
Serum 25(OH)D & 
1,25(OH)D2
232 414 No relation between vitamin D 
metabolite levels and prostate 
cancer
[222] Nurses' Health Study Dietary and 
supplement intake
Colon cancer RR = 0.42 (SS) 
for total vitamin D, comparing 
top and bottom quintiles
Calcium not related to 
colon cancer risks; 2.4 
fold reduction
[223] Finnish clinical cohort Serum 25(OH)D & 
1,25(OH)D2
146 292 ↑serum 25(OH)D = ↓risk of 
rectal cancer, RR by quartile = 
1.00, 0.93, 0.77, 0.37, P trend = 
0.06.
Serum 25(OH)D 12% 
lower in cases than in 
controls (12.2 vs 13.8 
ng/l, P = 0.01; 2.7-fold 
reduction
[224] NHANES I Follow-up 
Study
Sunlight and diet 190 
women
Cohort matched Risk reductions for breast 
cancer for women in regions 
with high solar radiation (RR 
0.35 – 0.75).
[225] Helsinki Heart Study Serum 25(OH)D 149 596 ↑serum 25(OH)D = ↓prostate 
cancer. 1.7 fold greater risk for 
below median level compared 
to above median level.
Young men (<52 years 
old) with low 25(OH)D 
had much higher risk of 
advanced prostate 
cancer (OR = 6.3)
[226] Randomized 
controlled trial for 
colon adenoma 
recurrence
Serum 25(OH)D & 
1,25(OH)D2, and 
supplementary 
calcium
803 
subjects 
total
Above medium 25(OH)D and 
supplemental calcium reduced 
adenoma recurrence (RR = 
0.71)
Calcium and vitamin D 
appeared to work 
together to reduce 
colon cancer risk.
[227] Norway, Finland, 
Sweden cohort of 
men
Serum 25(OH)D 622 1,451 ≤ 19 nmol/l and ≥ 80 nmol/l of 
25(OH)D at higher risk of 
prostate cancer. (40–60 nmol/l 
had lowest risk).Nutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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However, there is a large body of literature that indicates
that dietary carotenoids are cancer preventative (See Table
6). Alpha-carotene has been found to be a stronger protec-
tive agent than its well-known isomer β-carotene. Studies
tend to agree that overall intake of carotenoids is more
protective than a high intake of a single carotenoid. So, a
variety of fruits and vegetables is still a better anti-cancer
strategy than just using a single vegetable high in a specific
carotenoid.
The richest source of α-carotene is carrots and carrot juice,
with pumpkins and winter squash as a second most-dense
source. There is approximately one µg of α-carotene for
every two µg of β-carotene in carrots. The most common
sources of β-cryptoxanthin are citrus fruits and red sweet
peppers.
Lycopene
Of the various carotenoids lycopene has been found to be
very protective, particularly for prostate cancer. The major
dietary source of lycopene is tomatoes, with the lycopene
in cooked tomatoes being more bioavailable than that in
raw tomatoes. Several prospective cohort studies have
found associations between high intake of lycopene and
reduced incidence of prostate cancer, though not all stud-
ies have produced consistent results [144,145]. Some
studies suffer from a lack of good correlation between lyc-
opene intake assessed by questionnaire and actual serum
levels, and other studies measured intakes among a popu-
lation that consumed very few tomato products. The stud-
ies with positive results will be reviewed here.
Table 6: Studies of Carotenoids and Lung Cancer.
Reference Study # Cases # Controls Outcomes Comment
[228] Hawaiian cohort 332 865 Dose-dependent inverse associations for 
dietary β-carotene, α-carotene, lutein; 
Subjects with highest intake of all 3 had the 
lowest risk
Previous study showed variety of 
vegetables more protective than 
just foods rich in a particular 
carotenoid
[229] Washington county, 
Maryland residents
258 515 ↑Serum/plasma levels of cryptoxanthin, β-
carotene, lutein/zeaxanthin = ↓cancer (OR = 
0.74, 0.83, 0.90, SS)
[230] Case control, Spain 103 206, hospital No association for intake of α-carotene, β-
carotene, or lutein.
[231] Case control, Uruguay 541 540 ↑total carotenoids = ↓cancer (OR = 0.43, SS) Risk reduction for vit E and 
glutathione also seen.
[232] Finland cohort 138 ↑α-carotene = ↓cancer (OR = 0.61, SS); β-
carotene inversely related but not SS.
90% of α-carotene from carrots
↑Fruits and ↑root vegetables = 
↓cancer (OR = 0.58, 0.56, 
respectively, SS)
[233] Nurses' Health Study 
& Health Professionals 
Follow-Up Study
794 ↑α-carotene, lycopene, total carotenoids = 
↓cancer (OR = 0.75, 0.80, 068 respectively, 
SS); Never smokers + ↑α-carotene = ↓cancer 
(OR = 0.37, SS)
4–8 year lag between diet 
assessment and date of diagnosis 
gave strongest correlations.
[234] Shanghai men's cohort 209 622 ↑serum β-cryptoxanthin = ↓cancer (OR 
quartiles = 1, 0.72, 0.42, 0.45, P-trend = 0.02); 
Smokers with above median level of total 
carotenoids had a SS 37% reduction in cancer 
risk
Study population had ~50% lower 
mean levels of serum carotenoids 
compared to US whites.
[235] Canadian National 
Breast Screening 
Study
155 5,631 Non-significant inverse trend in risk for α-
carotene and β-cryptoxanthin
β-cryptoxanthin most from citrus, 
red peppers
[236] Japan Collaborative 
Cohort Study
147 311 ↑α-carotene, β-carotene, canthaxanthin, total 
carotenoids = ↓risk (OR = 0.35, 0.21, 0.37, 
0.27 respectively, SS); lycopene and β-
cryptoxanthin reduce lung cancer risk, but 
not significantly
[237] Singapore Chinese 
Health Study
482 ↑dietary β-cryptoxanthin = ↓cancer risk (OR 
= 0.73, 0.63 for smokers, SS)
No significant associations of other 
carotenoids with lung cancer
[238] Pooled analysis of 7 
cohorts in USA and 
Europe
3,155 ↑ dietary β-cryptoxanthin = ↓lung cancer (OR 
= 0.76, SS)
Other dietary carotenoids not 
significantly related to lung cancer.
SS = statistically significant difference between comparison groups.Nutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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In the Health Professionals Follow-up Study there was a
21% decrease in prostate cancer risk, comparing the high-
est quintile of lycopene intake with the lowest quintile.
Combined intake of tomatoes, tomato sauce, tomato
juice, and pizza (which accounted for 82% of the lyco-
pene intake) were associated with a 35% lower risk of
prostate cancer. Furthermore, lycopene was even more
protective for advanced stages of prostate cancer, with a
53% decrease in risk [146]. A more recent follow-up
report on this same cohort of men confirmed these origi-
nal findings that lycopene or frequent tomato intake is
associated with about a 30–40% decrease in risk of pros-
tate cancer, especially advanced prostate cancer [147].
In addition to the two reports above a nested case control
study from the Health Professional Follow-up Study with
450 cases and controls found an inverse relation between
plasma lycopene and prostate cancer risk (OR 0.48)
among older subjects (>65 years of age) without a family
history of prostate cancer [148]. Among younger men
high plasma β-carotene was associated with a statistically
significant 64% decrease in prostate cancer risk. So, the
results for lycopene have been found for dietary intakes as
well as plasma levels.
In a nested case-control study from the Physicians' Health
Study cohort, a placebo-controlled study of aspirin and β-
carotene, there was a 60% reduction in advanced prostate
cancer risk (P-trend = 0.006) for those subjects in the pla-
cebo group with the highest plasma lycopene levels, com-
pared to the lowest quintile. The β-carotene also had a
protective effect, especially for those men with low lyco-
pene levels [149].
In addition to these observational studies, two clinical tri-
als have been conducted to supplement lycopene for a
short period before radical prostatectomy. In one study 30
mg/day of lycopene were given to 15 men in the interven-
tion group while the 11 men were in the control group
were instructed to follow the National Cancer Institute's
recommendations to consume at least 5 servings of fruits
and vegetables daily. Results showed that the lycopene
slowed the growth of prostate cancer. Prostate tissue lyco-
pene concentration was 47% higher in the intervention
group. Subjects that took the lycopene for 3 weeks had
smaller tumors, less involvement of the surgical margins,
and less diffuse involvement of the prostate by pre-cancer-
ous high-grade prostatic intraepithelial neoplasia [150].
In another study before radical prostatectomy surgery 32
men were given a tomato sauce-based pasta dish every
day, which supplied 30 mg of lycopene per day. After 3
weeks serum and prostate lycopene levels increaed 2-fold
and 2.9-fold, respectively. PSA levels decreased 17%, as
seen also by Kucuk et al [150]. Oxidative DNA damage
was 21% lower in subjects' leukocytes and 28% lower in
prostate tissue, compared to non-study controls. The
apoptotic index was 3-fold higher in the resected prostate
tissue, compared to biopsy tissue [151]. These interven-
tion studies raise the question of what could have been
done in this intervention was longer and combined syner-
gistically with other effective intervention methods, such
as flax seed, increased selenium and possibly vitamin E, in
the context of a diet high in fruits and vegetable?
Vitamin C
Vitamin C, or ascorbic acid, has been studied in relation
to health and is the most common supplement taken in
the USA. Low blood levels of ascorbic acid are detrimental
to health (for a recent article see Fletcher et al [152]) and
vitamin C is correlated with overall good health and can-
cer prevention [153]. Use of vitamin C for cancer therapy
was popularized by Linus Pauling. At high concentrations
ascorbate is preferentially toxic to cancer cells. There is
some evidence that large doses of vitamin C, either in
multiple divided oral doses or intravenously, have benefi-
cial effects in cancer therapy [154-156]. Oral doses, even
in multiple divided doses, are not as effective as intrave-
nous administration. Vitamin C at a dose of 1.25 g admin-
istered orally produced mean peak plasma concentrations
of 135 ± 21 µmol/L compared with 885 ± 201 µmol/L for
intravenous administration [154].
While vitamin C is quite possibly an effective substance,
the amounts required for these therapeutic effects are
obviously beyond dietary intakes. However, intravenous
ascorbate may be a very beneficial adjuvant therapy for
cancer with no negative side effects when administered
properly.
Other Antioxidants
There are many more substances that will have some ben-
efit for cancer therapy. Most of these substances are found
in foods, but their effective doses for therapy are much
higher than the normal concentration in the food. For
example, grape seed extract contains proanthocyanidin,
which shows anticarcinogenic properties (reviewed by
Cos et al \ [157]. Also, green tea contains a flavanol, epi-
gallocatechin-3-gallate (EGCG), which can inhibit metal-
loproteinases, among several possible other mechanisms
[158]. And there are claims for various other herbal sub-
stances and extracts that might be of benefit, which are
beyond the scope of this review.
Probiotics
The bacteria that reside in the intestinal tract generally
have a symbiotic relationship with their host. Beneficial
bacteria produce natural antibiotics to keep pathogenic
bugs in check (preventing diarrhea and infections) and
produce some B vitamins in the small intestine where they
can be utilized. Beneficial bacteria help with food diges-Nutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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tion by providing extra enzymes, such as lactase, in the
small intestine. Beneficial bacteria help strengthen the
immune system right in the gut where much of the
interaction between the outside world and the body goes
on. Beneficial bacteria can help prevent food allergies.
They can help prevent cancer at various stages of
development. These good bacteria can improve mineral
absorption, maximizing food utilization.
However, the balance of beneficial and potentially patho-
genic bacteria in the gut is dependent on the diet. Vegeta-
ble fiber encourages the growth of beneficial bacteria. A
group of Adventist vegetarians was found to have a higher
amount of beneficial bacteria and lower amount of poten-
tially pathogenic bacteria compared to non-vegetarians
on a conventional American diet [159]. Differences in
bacterial populations were seen between patients who
recently had a colon polyp removed, Japanese-Hawaiians,
North American Caucasians, native rural Japanese, and
rural native Africans. Lactobacillus species and Eubacterium
aerofaciens, both producers of lactic acid, were associated
with the populations with the lower risk of colon cancer,
while Bacteroides and Bifidobacterium species were associ-
ated with higher risk of colon cancer [160]
There is a solid theoretical basis for why probiotics should
help prevent cancer, especially colon cancer, and even
reverse cancer. Probiotics produce short chain fatty acids
in the colon, which acidify the environment. Lower colon
pH is associated with lower incidence of colon cancer.
Probiotic bacteria reduce the level of procarcinogenic
enzymes such as beta-glucuronidase, nitroreductase, and
azoreductase [161].
L. casei was used in two trials of patients with superficial
bladder cancer. In the first trial, the probiotic group had a
50% disease free time of 350 days, compared to 195 days
for the control group [162]. The second trial also showed
that the probiotics worked better than the placebo, except
for multiple recurring tumors [163].
Except for the two studies noted above, most of the
research of probiotics and cancer has been done in ani-
mals. Studies have looked at markers of tumor growth or
at animals with chemically induced tumors.
Studies in rats have shown that probiotics can inhibit the
formation of aberrant crypt foci, thought to be a pre-can-
cerous lesion in the colon. Some of the best results were
obtained with a probiotic strain consumed with inulin, a
type of fructooligosaccharide. Total aberrant crypt foci,
chemically induced, were reduced 74% by the treatment
of rats with inulin and B. longum, but only 29 and 21% by
B. longum and inulin alone, respectively [164]. There was
a synergistic effect in using both products together. Simi-
lar synergy was seen in rats with azoxymethane-induced
colon cancer in another study. Rats fed Raftilose, a mix-
ture of inulin and oligofructose, or Raftilose with Lactoba-
cilli rhamnosus (LGG) and Bifidobacterium lactis (Bb12)
had a significantly lower number of tumors compared to
the control group [165]. A probiotic mixture, without any
prebiotic, given to rats fed azoxymethane reduced colon
tumors compared to the control (50% vs 90%), and also
reduced the number of tumors per tumor-bearing rat
[166].
In lab mice bred to be susceptible to colitis and colon can-
cer, a probiotic supplement, Lactobacillus salivarium ssp.
Salivarius  UCC118, reduced fecal coliform levels, the
number of potentially pathogenic Clostridium perfringens,
and reduced intestinal inflammation. In this small study
two mice died of fulminant colitis and 5 mice developed
adenocarcinoma in the control group of 10 mice, while
there was no colitis and only 1 mouse with adenocarci-
noma in the probiotic test group [167].
The research on probiotics and disease is still an emerging
field. There is a high degree of variation of health benefits
between different strains of bacteria. As new methods for
selecting and screening probiotics become available, the
field will be able to advance more rapidly.
Oral Enzymes
Many people diagnosed with cancer have digestion or
intestinal tract disorders as well. Impaired digestion will
greatly hinder a nutritional approach to treating cancer. If
the nutrients cannot be released from the food and taken
up by the body, then the excellent food provided by the
Hallelujah Diet will go to waste. Digestive enzyme supple-
ments are used to ensure proper and adequate digestion of
food. Even raw foods, which contain many digestive
enzymes to assist in their digestion, will be more thor-
oughly digested with less of the body's own resources with
the use of digestive enzymes. So, the enzymes taken with
meals do not have a direct effect upon a tumor, but assist
the body in getting all of the nutrition out of the food for
healing and restoring the body to normal function.
Recently, an in vitro system was used to test the use of sup-
plemental digestive enzymes. The digestive enzymes
improved the digestibility and bioaccessibility of proteins
and carbohydrates in the lumen of the small intestine, not
only under impaired digestive conditions, but also in
healthy human digestion [168].
There is evidence that indicates the presence of an entero-
pancreatic circulation of digestive enzymes [169]. Diges-
tive enzymes appear to be preferentially absorbed into the
bloodstream and then reaccumulated by the pancreas for
use again. There appears to be a mechanism by which
digestive enzymes can reach systemic circulation.Nutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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Enzymes, especially proteases, if they reach systemic circu-
lation, can have direct anti-tumor activity. Wald et al
[170] reported on the anti-metastatic effect of enzyme
supplements. Mice inoculated with the Lewis lung carci-
noma were treated with a proteolytic enzyme supplement,
given rectally (to avoid digestion). The primary tumor was
cut out, so that the metastatic spread of the cancer could
be measured. After surgical removal of the primary tumor
(day 0), 90% of the control mice died by day 18 due to
metastasized tumors. In the first group, which received the
rectal enzyme supplement from the time of the tumor-
removal surgery, 30% of the mice had died from metasta-
sized cancer by day 25. In the second group, which
received the enzymes from 6 days prior to removal of the
primary tumor, only 10% of the animals showed the met-
astatic process by day 15. In the third group, which
received the enzyme treatment since the initial inocula-
tion of the Lewis lung carcinoma, no metastatic spread of
the tumor was discernible. One hundred day-survival
rates for the control, first, second, and third groups were
0, 60%, 90%, and 100%.
In a similar experiment, an enzyme mixture of papain,
trypsin, and chymotrypsin, as used in the preparation
Wobe-Mugos E, was rectally given to mice that were inoc-
ulated with melanoma cells. Survival time was prolonged
in the test group (38 days in the enzyme group compared
to 24 days in the control mice) and 3 of the 10 enzyme-
supplemented mice were cured. Again, a strong anti-met-
astatic effect of the proteolytic enzymes was seen [171].
Further evidence of the efficacy of oral enzyme supple-
mentation is available from clinical trials in Europe. Two
different studies have demonstrated that two different
oral proteolytic enzyme supplements were able to reduce
high levels of transforming growth factor-β, which may be
a factor in some cancers [172,173]. In the Slovak Republic
an oral enzyme supplement was tested in a placebo-con-
trolled trial of multiple myeloma. For stage III multiple
myeloma, control group survival was 47 months,
compared to 83 months (a 3 year gain) for patients who
took the oral enzymes for more than 6 months [174].
Enzyme supplements have also been shown to reduce side
effects of cancer therapy. Enzyme supplementation
resulted in fewer side effects for women undergoing radi-
ation therapy for carcinomas of the uterine cervix [175],
for patients undergoing radiation therapy for head and
neck cancers [176], and for colorectal cancer patients
undergoing conventional cancer treatments [177]. In a
large multi-site study in Germany women undergoing
conventional cancer therapy were put into a control group
or a group that received an oral enzyme supplement. Dis-
ease and therapy related symptoms were all reduced,
except tumor pain, by the enzyme supplement. Also, sur-
vival was longer with less recurrence and less metastases in
the enzyme group [178]. In all of these studies the oral
enzyme supplements were well tolerated, with only a
small amount of mild to moderate gastrointestinal
symptoms.
Even though these few studies don't give a lot of evidence
of the effectiveness of oral enzyme supplementation, it is
clear that there are some circumstances that will be helped
by enzyme supplementation, with very little danger of
negative side effects. At the least, enzymes will improve
digestion and lessen the digestive burden on the body,
leaving more reserves for disease eradication. However, as
the research indicates, the effect may be much greater than
that, with the potential for direct anti-tumor activity.
Whole Diet Studies
A diet-based cancer therapy, the Gerson Therapy, was used
to treat melanoma cancer. The five-year survival rates
from their therapy compared very favorably to conven-
tional therapy reported in the medical literature, espe-
cially for more advanced stages of melanoma [179] (see
Table 7).
An Italian cohort of 8,984 women was followed for an
average of 9.5 years, with 207 incident cases of breast
cancer during that time. Their diets were analyzed by pat-
terns – salad vegetables (raw vegetables and olive oil),
western (potatoes, red meat, eggs and butter), canteen
(pasta and tomato sauce), and prudent (cooked
vegetables, pulses, and fish). Only the salad vegetable diet
pattern was associated with a significantly lower risk of
breast cancer, about 35% lower. For women of normal
weight (BMI <25) the salad vegetable pattern was even
more protective, about a 61% decreased risk of breast can-
cer [180]. The overall dietary pattern does make a very sig-
nificant difference.
In US-based studies the "prudent" diet has been shown to
be protective for colon cancer, while the "western" diet
has been shown to be detrimental. The "western" dietary
pattern, with its higher intakes of red meat and processed
meats, sweets and desserts, French fries, and refined
grains, was associated with a 46% increase relative risk of
Table 7: Gerson Therapy for Melanoma [179].
Stage of melanoma Gerson Historical controls
I – II 100% (N = 14) 79% (N = 15,798)
IIIA 82% (N = 17) 39% (N = 103)
IIIA + IIIB 70% (N = 33) 41% (N = 130)
IVA 39% (N = 18) 6% (N = 194)Nutrition Journal 2004, 3:19 http://www.nutritionj.com/content/3/1/19
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colon cancer in the Nurses' Health Study [45]. Slattery et
al [17] found a two-fold increase in relative risk of colon
cancer associated with a "western" dietary pattern, and a
35–40% decrease in relative risk associated with the "pru-
dent" pattern, especially among those diagnosed at an ear-
lier age (<67 years old). The "salad vegetable" pattern is
still more likely to be protective compared to the prudent
dietary pattern, but this pattern did not exist in this study
population.
In an analysis of the colon cancer data from the Health
Professionals Follow-up Study, Platz et al [56] found that
there was a 71% decrease in colon cancer risk when men
with none of six established risk factors were compared to
men with at least one of these risk factors (obesity, physi-
cal inactivity, alcohol consumption, early adulthood ciga-
rette smoking, red meat consumption, and low intake of
folic acid from supplements). So, if all men had the same
health profile as these healthier 3% of the study
population, colon cancer rates would have been only 29%
of what they measured.
A plant-based dietary pattern in being currently tested in
the Women's healthy Eating and Living (WHEL) Study.
About 3,000 women who were treated for an early stage of
breast cancer have been randomized into two groups. The
dietary goals for the test group of the study are 5 servings
of vegetables, 16 oz of vegetable juice, 3 servings of fruit,
30 g of fiber, and <20% of energy from fat. No guidelines
were given for animal product intake, and initial results
seem to confirm, since there were no changes in body
weight, total cholesterol, or LDL cholesterol [181], which
would be affected by animal protein intake. However,
over the first year of follow-up vegetable intake did
increase to seven servings/day, fruit intake increased to 3.9
servings/day, energy from fat decreased from 28% to 23%.
Also, plasma carotenoid concentrations increased signifi-
cantly in the intervention group, but not in the control
group. α-Carotene increased 223%, β-carotene increased
87%, lutein increase 29%, and lycopene increased 17%
[182], indicating that a substantial dietary change had
been made by these women. It will be very interesting to
follow the results of this study.
Conclusions
What is the result when all of these things are put
together? What if all of these factors reviewed here were
taken into account and put into practice? This anticancer
diet would have:
• adequate, but not excessive calories,
• 10 or more servings of vegetables a day, including cruci-
ferous and allium vegetables; vegetable juice could meet
part of this goal,
• 4 or more servings of fruits a day,
• high in fiber,
• no refined sugar,
• no refined flour,
• low in total fat, but containing necessary essential fatty
acids,
• no red meat,
• a balanced ratio of omega 3 and omega 6 fats and would
include DHA,
• flax seed as a source of phytoestrogens,
• supplemented with ~200 µg/day selenium,
• supplemented with 1,000 µg/day methylcobalamin (B-
12),
• very rich in folic acid (from dark green vegetables),
• adequate sunshine to get vitamin D, or use 1,000 IU/day
supplement,
• very rich in antioxidants and phytochemicals from fruits
and vegetables, including α-carotene, β-carotene, β-cryp-
toxanthin, vitamin C (from foods), vitamin E (from
foods),
• very rich in chlorophyll,
• supplemented with beneficial probiotics,
• supplemented with oral enzymes
As reviewed above, reductions of 60 percent in breast can-
cer rates have already been seen in human diet studies,
and a 71 percent reduction in colon cancer for men with-
out the known modifiable risk factors. These reductions
are without taking into account many of the other factors
considered in this review, such as markedly increased fruit
and vegetable intake, balanced omega 3 and 6 fats, vita-
min D, reduced sugar intake, probiotics, and enzymes –
factors which all are likely to have an impact on cancer.
Certainly cancer prevention would be possible, and can-
cer reversal in some cases is quite likely.
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